HCP, Inc. (NYSE:HCP) Shares Bought by Metropolitan Life Insurance Co NY

Share on StockTwits

Metropolitan Life Insurance Co NY grew its position in shares of HCP, Inc. (NYSE:HCP) by 0.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 96,555 shares of the real estate investment trust’s stock after acquiring an additional 743 shares during the quarter. Metropolitan Life Insurance Co NY’s holdings in HCP were worth $3,440,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. State Street Corp boosted its holdings in shares of HCP by 3.0% during the third quarter. State Street Corp now owns 36,139,545 shares of the real estate investment trust’s stock valued at $1,287,652,000 after acquiring an additional 1,046,182 shares during the period. Barrow Hanley Mewhinney & Strauss LLC raised its stake in shares of HCP by 11.3% during the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 14,177,081 shares of the real estate investment trust’s stock valued at $453,383,000 after purchasing an additional 1,441,636 shares in the last quarter. Invesco Ltd. raised its stake in shares of HCP by 6.6% during the second quarter. Invesco Ltd. now owns 12,663,750 shares of the real estate investment trust’s stock valued at $404,988,000 after purchasing an additional 788,307 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of HCP by 10.1% during the second quarter. JPMorgan Chase & Co. now owns 12,570,846 shares of the real estate investment trust’s stock valued at $399,752,000 after purchasing an additional 1,150,685 shares in the last quarter. Finally, Resolution Capital Ltd raised its stake in shares of HCP by 11.1% during the third quarter. Resolution Capital Ltd now owns 9,733,993 shares of the real estate investment trust’s stock valued at $346,822,000 after purchasing an additional 976,101 shares in the last quarter. 95.80% of the stock is owned by institutional investors.

Shares of HCP stock opened at $34.88 on Monday. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.01. The company’s 50-day moving average price is $35.57 and its two-hundred day moving average price is $33.82. HCP, Inc. has a 52 week low of $26.58 and a 52 week high of $37.93. The stock has a market cap of $17.13 billion, a PE ratio of 19.16, a price-to-earnings-growth ratio of 6.81 and a beta of 0.22.

HCP (NYSE:HCP) last issued its quarterly earnings results on Wednesday, October 30th. The real estate investment trust reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.43 by ($0.52). HCP had a return on equity of 12.78% and a net margin of 43.66%. The business had revenue of $538.00 million during the quarter, compared to the consensus estimate of $503.65 million. During the same quarter last year, the firm posted $0.44 earnings per share. HCP’s revenue was up 18.0% compared to the same quarter last year. On average, equities analysts predict that HCP, Inc. will post 1.75 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, November 19th. Shareholders of record on Monday, November 4th were given a $0.37 dividend. This represents a $1.48 annualized dividend and a yield of 4.24%. The ex-dividend date of this dividend was Friday, November 1st. HCP’s dividend payout ratio (DPR) is presently 81.32%.

In other HCP news, COO Thomas Klaritch sold 35,014 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $36.02, for a total value of $1,261,204.28. Following the sale, the chief operating officer now directly owns 230,529 shares in the company, valued at $8,303,654.58. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.13% of the stock is currently owned by insiders.

A number of equities research analysts recently weighed in on the stock. Stifel Nicolaus lifted their price objective on shares of HCP from $34.00 to $37.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. They noted that the move was a valuation call. Barclays lifted their price objective on shares of HCP from $37.00 to $39.00 and gave the company an “overweight” rating in a research note on Wednesday, October 2nd. Scotiabank set a $38.00 price objective on shares of HCP and gave the company a “buy” rating in a research note on Monday, September 30th. KeyCorp lifted their price objective on shares of HCP from $34.00 to $37.00 and gave the company an “overweight” rating in a research note on Wednesday, October 2nd. Finally, Argus upgraded shares of HCP from a “hold” rating to a “buy” rating in a research note on Tuesday, September 10th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $36.78.

HCP Profile

HCP, Inc is a fully integrated real estate investment trust (REIT) that invests in real estate serving the healthcare industry in the United States. HCP owns a large-scale portfolio primarily diversified across life science, medical office and senior housing. Recognized as a global leader in sustainability, HCP has been a publicly-traded company since 1985 and was the first healthcare REIT selected to the S&P 500 index.

See Also: Understanding Specialty Certificates of Deposit

Want to see what other hedge funds are holding HCP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCP, Inc. (NYSE:HCP).

Institutional Ownership by Quarter for HCP (NYSE:HCP)

Receive News & Ratings for HCP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCP and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.